Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
The current project applies an integrative three-prong approach to investigate the potential
of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic
satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake,
and 3) examines a genetic predisposition that may markedly impact the effectiveness of this
medication in those at high risk for T2DM.